400 Shares in Agilent Technologies, Inc. (NYSE:A) Bought by Banque Transatlantique SA

Banque Transatlantique SA purchased a new position in Agilent Technologies, Inc. (NYSE:A) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 400 shares of the medical research company’s stock, valued at approximately $53,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. CKW Financial Group raised its holdings in Agilent Technologies by 114.9% during the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Global X Japan Co. Ltd. raised its holdings in shares of Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after acquiring an additional 116 shares during the last quarter. Redwood Park Advisors LLC bought a new position in Agilent Technologies in the 4th quarter valued at about $27,000. Lee Danner & Bass Inc. acquired a new position in Agilent Technologies during the 4th quarter valued at about $29,000. Finally, Hanson & Doremus Investment Management increased its holdings in Agilent Technologies by 66.5% during the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock worth $35,000 after purchasing an additional 105 shares in the last quarter.

Insider Activity

In related news, VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $116.46, for a total transaction of $211,840.74. Following the sale, the director now owns 35,737 shares of the company’s stock, valued at approximately $4,161,931.02. The trade was a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $108.68 on Monday. The company has a 50-day moving average price of $113.57 and a two-hundred day moving average price of $129.71. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $155.35. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $30.98 billion, a PE ratio of 24.98, a P/E/G ratio of 3.06 and a beta of 1.27.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Equities analysts forecast that Agilent Technologies, Inc. will post 5.54 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st were issued a dividend of $0.248 per share. This represents a $0.99 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date was Tuesday, April 1st. Agilent Technologies’s payout ratio is presently 22.76%.

Analyst Upgrades and Downgrades

A has been the subject of several recent research reports. Wells Fargo & Company decreased their price target on Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a report on Thursday, April 17th. Barclays lowered their target price on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Jefferies Financial Group cut their price target on shares of Agilent Technologies from $135.00 to $116.00 and set a “hold” rating on the stock in a report on Monday, April 21st. Robert W. Baird decreased their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a research note on Thursday, February 27th. Finally, TD Cowen upped their target price on Agilent Technologies to $135.00 and gave the company a “buy” rating in a report on Thursday, April 10th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $143.00.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.